Dover Corp vs Humana Inc — how do they compare? Dover Corp trades at $189.15 (market cap $25.45B), while Humana Inc trades at $436 (market cap $46.49B). The key difference: Humana Inc is the larger of the two by market cap, and Dover Corp pays the higher dividend (1.11%). Which is the better fit depends on your goals — on Pluang, investors hold Dover Corp for 73 Days and Humana Inc for 51 Days on average.
| DOV | HUM | |
|---|---|---|
Market Cap | $25.45B | $46.49B |
Volume | 661,758 | 2,567,704 |
Sector | Industrials | Health |
52-Week High | $233.31 | $409.85 |
52-Week Low | $161.16 | $163.67 |
Typical Hold Time | 73 Days | 51 Days |
Enterprise Value | $26.95B | $53.84B |
Dividend Yield | 1.11% | 0.91% |
Signals from Pluang's Aura AI — not financial advice
Dover Corporation (DOV) trades at $188.83, up 0.29% with a bearish technical signal despite strong fundamentals. The stock shows consistent earnings beats with Q2 2026 EPS of $2.74 exceeding expectations, supported by robust profitability margins including 39.58% gross margin and 13.48% net income margin. Recent acquisitions and product launches demonstrate ongoing business expansion.
Analyst consensus remains strongly bullish with a $243.20 price target representing 29% upside potential. Key risks include technical weakness and cyclical industrial exposure, but strong cash flow generation and dividend history provide stability. The combination of earnings momentum and institutional support suggests long-term value despite near-term technical headwinds.
Humana (HUM) trades at $431.03, up 8.71% over the past day, reflecting strong momentum following a Barclays upgrade and positive earnings beats. The stock exhibits a bullish technical trend, with support at $378 and resistance at $394. Revenue has grown steadily from $92.9B in 2022 to $129.7B in 2025, though net income margins have compressed to 0.88%. Analyst consensus is a Buy with a $457.05 price target, and recent news highlights corporate initiatives and institutional investments.
The outlook for HUM is cautiously optimistic, driven by revenue growth and analyst support, but risks include margin pressure and regulatory scrutiny. Investment opportunity lies in execution of Medicare Advantage strategies, while key risks involve competitive pressures and potential fiduciary concerns highlighted in recent shareholder notices.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Dover is a diversified industrial manufacturing company with products and services that include digital printing for fast-moving consuming goods, marking and coding for the food and beverage industry, loaders for the waste collection industry, pumps for the transport of fluids, including petroleum and natural gas, and commercial refrigerators used in groceries and convenience stores. Most of the business operates in the United States. After the spinoff of Apergy, the company operates through five segments: engineered systems, clean energy and fueling solutions, imaging and identification, pumps and process solutions, and climate and sustainability technologies equipment.
Read more on DOV →Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →